Ultrasonic Assessment of Hepatic Blood Flow as a Marker of Mouse Hepatocarcinoma

Bonnin, Philippe; Villemain, Aude; Vincent, François; Debbabi, Haythem; Silvestre, Jean‐Sébastien; Contreres, Jean Olivier; Lévy, Bernard; Tobelem, Gérard; Dupuy, Évelyne

doi:10.1016/j.ultrasmedbio.2006.09.010

Cited by 28 publications

(35 citation statements)

References 35 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Normally, the liver vasculature is mainly supplied by the portal vein (80%) and 20% by the hepatic artery. In HCC-TG mice, the arterial phase is markedly increased (22). Here, we observed a concomitant decrease in arterial inflow and arterial vessel density in bitransgenic mice until 16 weeks.…”

Section: Discussionsupporting

confidence: 52%

“…Wild-type C57/BL6 mice were used as controls (n = 8). We previously showed that the liver volume, assessed by ultrasound, increased with the progression of hepatocarcinoma (22). Thus, we estimate that the liver volume reflected tumor growth.…”

Section: Methodsmentioning

confidence: 77%

“…Arterial blood flow velocities recorded upstream from an organ give information on the development of the downstream vessels, vascular resistance, and represent a functional assessment of vessels (26). Thus, hepatic blood velocities recorded in the hepatic artery was used to assess downstream vessels functionality, i.e., an increase in HCC-TG mice related to abnormal liver vessels (22). Here, hepatic artery blood flow velocities were lowered in bitransgenic mice from 4 to 16 weeks without any significant difference compared with wild-type mice until 12 weeks.…”

Section: Discussionmentioning

confidence: 99%

“…Mice were subjected to ultrasound measurements using an echocardiograph (Vivid 7, GE Medical Systems Ultrasound) equipped with a 12-MHz linear transducer. Ultrasound study of the liver and time-averaged mean blood flow velocities measured in the hepatic and mesenteric arteries were performed in these mice as previously described (22). All ultrasound measurements were performed in the three transgenic mouse groups (HCC-TG (n = 12), HCC/Hu-AGT-TG (n = 12), Hu-AGT-TG (n = 8) mice) at different ages (4-24 weeks) corresponding to the main stages of hepatocarcinoma.…”

Section: Methodsmentioning

confidence: 99%

“…We have shown that endothelial arterial markers such as Delta-like 4 ligand (Dll4), active Notch4, and ephrin B2 (17)(18)(19)(20) are gradually upregulated during hepatocarcinoma progression (21). In this model, we have also developed noninvasive measurements of liver volume and neovascularization by conventional two-dimensional colorcoded pulsed Doppler ultrasound imaging, allowing us to follow the efficacy of potential antiangiogenic factors (22). Because AGT is mainly synthesized in the liver, our bitransgenic mouse model is appropriated to study the potential antiangiogenic effect of AGT.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Angiotensinogen Delays Angiogenesis and Tumor Growth of Hepatocarcinoma in Transgenic Mice

et al. 2009

Self Cite

View full text Add to dashboard Cite

Angiotensinogen, a member of the serpin family, is involved in the suppression of tumor growth and metastasis. To investigate whether human angiotensinogen protects against tumor progression in vivo, we established an original bitransgenic model in which transgenic mice expressing human angiotensinogen (Hu-AGT-TG mice) were crossed with a transgenic mouse model of hepatocellular carcinoma (HCC-TG mice). Bitransgenic mice overexpressing human angiotensinogen (HCC/Hu-AGT-TG) had a significantly longer survival time than the HCC-TG mice and a reduction of both tumor growth and blood flow velocities in the liver. This antitumor effect of angiotensinogen is related to a reduced angiogenesis, impaired expression of endothelial arterial markers (active Notch4, Delta-like 4 ligand, and ephrin B2) with a decrease of arterial vessel density in HCC/Hu-AGT-TG mice liver. Overexpression of human angiotensinogen decreases angiogenesis, and prevents tumor sinusoids from remodeling and arterialization, thus delaying tumor progression in vivo.

show abstract

Section: Discussionsupporting

confidence: 52%

Section: Methodsmentioning

confidence: 77%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Angiotensinogen Delays Angiogenesis and Tumor Growth of Hepatocarcinoma in Transgenic Mice

et al. 2009

Self Cite

View full text Add to dashboard Cite

show abstract

MRI‐guided interventional natural killer cell delivery for liver tumor treatment

Wang

Zheng

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

While natural killer (NK) cell‐based adoptive transfer immunotherapy (ATI) provides only modest clinical success in cancer patients. This study was hypothesized that MRI‐guided transcatheter intra‐hepatic arterial (IHA) infusion permits local delivery to liver tumors to improve outcomes during NK‐based ATI in a rat model of hepatocellular carcinoma (HCC). Mouse NK cells were labeled with clinically applicable iron nanocomplexes. Twenty rat HCC models were assigned to three groups: transcatheter IHA saline infusion as the control group, transcatheter IHA NK infusion group, and intravenous (IV) NK infusion group. MRI studies were performed at baseline and at 24 h, 48 h, and 8 days postinfusion. There was a significant difference in tumor R2* values between baseline and 24 h following the selective transcatheter IHA NK delivery to the tumors (P = 0.039) when compared to IV NK infusion (P = 0.803). At 8 days postinfusion, there were significant differences in tumor volumes between the control, IV, and IHA NK infusion groups (control vs. IV, P = 0.196; control vs. IHA, P < 0.001; and IV vs. IHA, P = 0.001). Moreover, there was a strong correlation between tumor R2* value change (∆R2*) at 24 h postinfusion and tumor volume change (∆volume) at 8 days in IHA group (R 2 = 0.704, P < 0.001). Clinically applicable labeled NK cells with 12‐h labeling time can be tracked by MRI. Transcatheter IHA infusion improves NK cell homing efficacy and immunotherapeutic efficiency. The change in tumor R2* value 24 h postinfusion is an important early biomarker for prediction of longitudinal response.

show abstract

RETRACTED ARTICLE: Comparison of preoperative ultrasound and MRI in the diagnosis of microvascular invasion in hepatocellular carcinoma

Long

Wang

et al. 2023

Funct Integr Genomics

View full text Add to dashboard Cite

Ultrasonic Assessment of Hepatic Blood Flow as a Marker of Mouse Hepatocarcinoma

Cited by 28 publications

References 35 publications

Angiotensinogen Delays Angiogenesis and Tumor Growth of Hepatocarcinoma in Transgenic Mice

Angiotensinogen Delays Angiogenesis and Tumor Growth of Hepatocarcinoma in Transgenic Mice

MRI‐guided interventional natural killer cell delivery for liver tumor treatment

RETRACTED ARTICLE: Comparison of preoperative ultrasound and MRI in the diagnosis of microvascular invasion in hepatocellular carcinoma

Contact Info

Product

Resources

About